Q3 2026 Portfolio Performance & Q4 Strategic Rotation

on


 In Q3 2026, our concentrated equity portfolio delivered a +1.25% net return, absorbing mid-quarter macroeconomic volatility before executing an +11.71% alpha sprint in September.

Quarterly reporting should evaluate structural thesis execution rather than short-term price movements. Across broader time horizons, our performance spread remains exceptionally wide:

  • 2026 Year-to-Date: +28.07% (vs. S&P 500 +12.89% and Nasdaq 100 +22.27%)

  • Since January 2024: +126.48% (vs. S&P 500 +59.53% and Nasdaq 100 +79.77%)

Anatomy of Q3: Drawdowns as a Statistical Property July and August subjected technology equities to sharp drawdowns. As bond yields crossed 5.0%, market participants rotated into defensive sectors. Our portfolio absorbed a peak drawdown of approximately -17%. Institutional asset managers frequently manage headline volatility by purchasing low-beta assets or raising cash. Smoothing intra-quarter variance by diluting capital impairs compounding returns. Because our holdings are governed by physical bottlenecks rather than consumer discretionary cycles, we maintained 99.98% capital deployment throughout the decline, fully capturing the violent mean-reversion in September.

Q3 End-of-Quarter Allocation

At the close of September, our top four positions represented 45.39% of our deployed assets, anchoring our thesis in hardware compute:

  • ASML: 12.75%

  • NVIDIA: 12.36%

  • AMD: 11.34%

  • Micron: 8.94%

Q4 Strategic Rotation Entering October, we executed a ~10% portfolio rotation. We liquidated Datadog to eliminate exposure to multiple contraction risks in a high-yield environment, and we exited SanDisk to control our aggregate memory concentration.

This capital was reallocated to expand our chokepoint thesis:

  1. Enterprise Data Ontology: We initiated Palantir (PLTR). Hardware compute is ineffective without structured data. Palantir operates as the definitive toll booth for institutional AI deployment.

  2. Biological Compute: We initiated Moderna (MRNA). We view this as an investment in a programmable biological platform—an mRNA chokepoint for next-generation therapeutics.

We enter the fourth quarter positioned aggressively in the foundational monopolies of both digital and biological infrastructure.

Copier Blueprint

I execute this exact allocation publicly on eToro. To mirror these positions:

  1. Search for razvancd.

  2. Click Copy and check "Copy Open Trades". Minimum recommended allocation: $500. Copy Trading is not investment advice | Capital at risk | Past performance does not guarantee future results.